LILRB2 (OR502 Biosimilar) Recombinant Monoclonal Antibody
-
貨號:CSB-RA839793MB6HU
-
規(guī)格:¥83486
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:LILRB2(OR502 Biosimilar Antibody)重組單克隆抗體是一款專為科研用途設(shè)計的生物試劑,靶向免疫調(diào)節(jié)受體LILRB2(白細胞免疫球蛋白樣受體B2)。該抗體通過重組DNA技術(shù)在哺乳動物細胞中表達,具備高純度、高特異性和良好的批次一致性,為免疫機制研究提供可靠工具。 LILRB2作為免疫球蛋白超家族成員,主要表達于 monocytes、巨噬細胞、 dendritic cells等髓系細胞表面,通過識別MHC I類分子及相關(guān)配體參與免疫抑制信號傳導(dǎo),在腫瘤免疫逃逸、自身免疫疾病及炎癥反應(yīng)中發(fā)揮關(guān)鍵調(diào)控作用。本產(chǎn)品可特異性結(jié)合LILRB2胞外結(jié)構(gòu)域,有效阻斷其與配體的相互作用,適用于、ELISA及體外功能實驗等多種研究場景。 該抗體經(jīng)嚴(yán)格的質(zhì)量控制,包括SDS-PAGE純度分析(≥95%)、內(nèi)毒素檢測(<0.1 EU/μg)及特異性驗證,確保實驗結(jié)果的準(zhǔn)確性與可重復(fù)性。其重組表達體系避免了動物源抗體的批次差異問題,且不含防腐劑和疊氮鈉等干擾性成分,可直接用于細胞培養(yǎng)體系。 作為基礎(chǔ)研究工具,LILRB2重組單克隆抗體為探索免疫檢查點調(diào)控機制、開發(fā)新型免疫治療靶點提供重要支持,尤其適用于腫瘤微環(huán)境免疫抑制通路、髓系細胞功能調(diào)控及自身免疫疾病發(fā)病機制等方向的研究。
-
Uniprot No.:
-
基因名:
-
別名:OR502 research-grade biosimilar; OR 502 research-grade biosimilar; OR-502 research-grade biosimilar ;LILRB2 antibody; ILT4 antibody; LIR2 antibody; MIR10 antibody; Leukocyte immunoglobulin-like receptor subfamily B member 2 antibody; LIR-2 antibody; Leukocyte immunoglobulin-like receptor 2 antibody; CD85 antigen-like family member D antibody; Immunoglobulin-like transcript 4 antibody; ILT-4 antibody; Monocyte/macrophage immunoglobulin-like receptor 10 antibody; MIR-10 antibody; CD antigen CD85d antibody
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human LILRB2 protein
-
免疫原種屬:Homo sapiens (Human)
-
標(biāo)記方式:Non-conjugated
-
克隆類型:Monoclonal
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:0.01M PBS,pH7.4
-
產(chǎn)品提供形式:Liquid
-
應(yīng)用說明:Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method. -
儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:3-4 weeks
-
用途:It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.
相關(guān)產(chǎn)品
靶點詳情
-
功能:Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Involved in the down-regulation of the immune response and the development of tolerance. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M) triggering differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance. Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
-
亞細胞定位:Cell membrane; Single-pass type I membrane protein.
-
組織特異性:Expressed in monocytes and at lower levels in myeloid and plasmacytoid dendritic cells. Expressed in tolerogenic IL10-producing dendritic cells. Expressed in myeloid-derived suppressor cells during pregnancy. Detected at low levels in natural killer (NK)
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-















